A collaboration between the Androgen Excess and PCOS Society (AEPCOS) and the European Society of Endocrinology
AE-PCOS Update meeting - novel therapies for the treatment of PCOS
Summary
Polycystic ovary syndrome (PCOS) remains one of the most common and complex endocrine disorders affecting women worldwide. This one-day satellite conference will bring together leading scientists and clinicians to explore emerging therapeutic strategies aimed at improving reproductive, metabolic, and psychological outcomes in PCOS.
Sessions will highlight advances in targeted pharmacological treatments, lifestyle and metabolic interventions, and novel approaches involving neuroendocrine, immune, and gut–brain pathways. This concentrated meeting is interdisciplinary and seeks to bridge basic biodiscovery insights with clinical translation toward better treatment for PCOS.
Programme
07:30 - 08:30 Registration and Introduction
Welcome
Melanie Cree (USA), Elisabet Stener-Victorin
AE-PCOS Society News
Terhi Piltonen (USA), Anuja Dokras (USA)
08:30 - 10:00 Session 1
A blocking antibody against anti-Müllerian hormone restores ovulation and normal androgen levels in a spontaneous rat model of polycystic ovary Syndrome
Nathalie di Clemente (France)
Cell type-specific endometrial dysfunctions across the menstrual cycle in polycystic ovary Syndrome
Tanja Turunen (Sweden)
Limited utility of cluster analysis in polycystic ovary syndrome for defining clinically meaningful subtypes and case–control discrimination in unselected populations
Helena Teede (Australia)
Targeting the Androgen Receptor to Treat Cardiometabolic Complications in PCOS
Damian Romero (USA)
10:00 - 10:30 Coffee Break
10:30 - 12:00 Session 2
GLP-1 and GLP-1/GIP receptor agonists in PCOS treatment
Mojca Jensterle (Slovenja)
Reduced circulating and skeletal muscle MOTS-c expression in women with polycystic ovary syndrome: Evidence for disrupted mitochondrial-derived peptide Regulation
Irem Sonmezoglu Kutuk (Turkey)
Increased prospective cardiovascular disease risk in 127,517 Nordic women with polycystic ovary syndrome. A national cohort study.
Dorte Glintborg (Denmark)
11:30 - 12:00 Selected rapid-fire talks
A lifestyle program to improve infertility in women with overweight or obesity tends to be particularly effective in polycystic ovary syndrome: An RCT subgroup Analysis
Christophe Richer dit Laflèche (Canada)
Pro-inflammatory cytokine profiling in polycystic ovary syndrome phenotypes: excess abdominal adiposity vs hyperandrogenism.
Martina Curcio (Italy)
The impact of waist to height ratio in the assessment of women with polycystic ovary syndrome. Evidence from a large European cohort.
Tamara Baltic (Greece)
Twelve-month clinical outcomes following transvaginal ultrasound-guided ovarian ablation in women with PCOS-related infertility: the ULTRA Trial
Saad Amer (UK)
Developing PCOS cell therapy using human GnRH cell repopulation in a GnRH-Killswitch mouse model
Jacob Short (Sweden)
12:00 - 13:00 Lunch
13:00 - 14:15 Session 3
Saroglitazar/ PPAR gamma agonist in PCOS Treatment
Farheen Shaikh (USA)
Unraveling the role of hyperandrogenism in the development of metabolic dysfunction-associated steatotic liver disease (MASLD) in polycystic ovary Syndrome
Andrea Rodriguez-Martin (Spain)
Manipulation of peripheral androgen signaling in the treatment of PCOS-associated metabolic dysfunction
Caitlin MacRae (New Zealand)
14:15 - 14:30 Coffee Break
14:30 - 16:15 Session 4
Targeting cannabinoids and incretins in the treatment of PCOS
Manuel Tena-Sempere (Spain)
Inhibition of the androgen-activating enzyme AKR1C3 selectively decreases systemic and intra-adipose 11-oxygenated androgens in women
Lina Schiffer (UK)
In vitro endometrium of insulin resistant women with polycystic ovary Syndrome
Anja Dekanski (Sweden)
15:30 - 16:00 Selected rapid-fire talks
Development of an immunodeficient prenatal mouse model of polycystic ovary syndrome for evaluation of new therapeutics
Camille Gauthier (Sweden)
Mechanistic insights into the effects of intranasal insulin in increasing postprandial energy expenditure in obese women with polycystic ovary Syndrome
Colin Duncan (UK)
Serum sex hormone binding globulin is inversely associated with 11-oxygenated androgens and insulin resistance in women with PCOS
Eka Melson (UK)
Steroid hormone levels across the menstrual cycle in women with PCOS: golden standard liquid-tandem mass spectrometry Analysis
Meri-Maija Ollila (Finland)
Genetic variation in the gonadotropin signaling pathway and its role in PCOS pathogenesis.
Giangela Stokes (USA)
The BRIDGE initiative: Empowering University Societies through Evidence-Based Workshops Co-created with Patient Support Groups to Support Women with PCOS
Sumaya Osman (UK)
16:00 - 16:15 Meeting wrap-up
Terhi Piltonen
You can also submit an abstract to present at this course on the main ECE 2026 abstract submission form, please tick the question if you would like you abstract to be considered for both events.
Date/time
Saturday, 9 May 2026 approx. 09:30-16:00 and will finish in time for delegates to attend the ECE 2026 Opening Ceremony.
Location
ECE 2026 venue: Prague Congress Centre (PCC) - South Hall 1B
Language
English
Who should attend
This course will be of interest to any health care professional or researcher with an interest in PCOS.
Delegate fee
The fees to attend this course are:
- €165 for ESE or AE-PCOS members
- €110 for ESE or AE-PCOS members in-training
- €220 for non-members.
Registration for this course is open, and available as an additional ticket on the main ECE 2026 registration system.
Registration details
You must register for this event through your ECE 2026 registration (you do not have to attend ECE 2026, but your registration will only be valid for the Pre-Congress Course).
Contact
For further information please contact the ECE 2026 Congress team on ece2026-congress@interplan.de
Focus Area
The content of the course fits within the ESE Focus Area of Reproduction and Developmental Endocrinology. For further details of ESE Focus Areas please click here.